Headlines about Rhythm Pharmaceuticals (NASDAQ:RYTM) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9025419251399 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

RYTM has been the subject of several research reports. Needham & Company LLC initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $32.00 target price for the company. Morgan Stanley initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “equal weight” rating and a $23.00 target price for the company. Cowen initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Bank of America initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $30.00 target price for the company.

Rhythm Pharmaceuticals (NASDAQ RYTM) opened at $27.01 on Wednesday. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Tuesday, November 14th. The company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($1.38). equities research analysts expect that Rhythm Pharmaceuticals will post -1.63 EPS for the current year.

In related news, insider James E. Flynn bought 355,000 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, October 10th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,035,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David P. Meeker bought 25,000 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, October 10th. The shares were bought at an average cost of $17.00 per share, with a total value of $425,000.00. The disclosure for this purchase can be found here. Insiders have purchased 1,285,000 shares of company stock valued at $21,845,000 in the last ninety days.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Rhythm Pharmaceuticals (RYTM) Stock Price” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-rhythm-pharmaceuticals-rytm-stock-price.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Stock Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related stocks with our FREE daily email newsletter.